Lisa Gilliam is an Endocrinology/Metabolic physician. OpenAlex indexes 77 publications with 2,382 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1959 NE Pacific St
University Of Washington Medical Ctr
Seattle, WA 981950001
Telephone
206-598-4882Registry record last updated 18 Jan 2022.
Clinical trials
- Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
Sponsor: Kaiser Permanente
- Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
Sponsor: Kaiser Permanente
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ethicon US, LLCProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
80.3%l-Thyroxine51.5%Levothyroxine Sodium100%Part D≥68 patientsThyroid Hormone Synthesis Inhibitor21.6%Methimazole100%Part D≥33 patients+ 2 more classes in this area
Metabolism & gastrointestinal
13.1%Insulin Analog9.9%Insulin Glargine-Yfgn65%Humalog35%Part D<11 patientsVitamin D3 Analog3.2%Calcitriol100%Part D<11 patientsSensory organs
6.7%Corticosteroid6.7%Hydrocortisone100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2006–2006 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparative safety of glucose‐lowering medications on depression in adults with type 2 diabetes
Diabetes Obesity and Metabolism
2026 - Deprescribing in Older Adults With Type 2 Diabetes: Associations With Patients' Perspectives: The Diabetes and Aging Study
Journal of the American Geriatrics Society
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”